George 2002.

Methods	BUPROPION Randomized controlled trial Setting: mental health clinic, USA Recruitment: outpatients
Participants	32 smokers with schizophrenia motivated to quit; 44% F, av. age 41/45, av. CPD 24
Interventions	1. Bupropion 300 mg/day for 9 weeks. TQD w3 2. Placebo Both arms: 10x 60 min weekly group therapy
Outcomes	Abstinence at 6m (7‐day PP) Validation: CO < 10 ppm
Notes	Funding: National institute on Drug Abuse, U.S. Department of Veterans Affairs, National Alliance for Research on Schizophrenia and Depression. Medication provided by GlaxoSmithKline.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomization method not described.
Allocation concealment (selection bias)	Unclear risk	Not described.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	"Both subjects and research staff were blinded to study medication assignment. Study medications were prepared by research pharmacists at CMHC, using encapsulation of SR bupropion tablets with blue 00 opaque capsules; placebo capsules contained only a dextrose matrix."
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Number followed‐up at 6m not reported."Subjects who were lost during the trial or at 6‐month follow‐up were counted as smokers."